country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-Q66655

Copy Link Print Information

YRDC-IN-1

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

YRDC-IN-1 is a blood-brain barrier-permeable YRDC inhibitor. YRDC is a key enzyme that catalyzes the formation of N⁶-threonylcarbamoyladenosine at position 37 of tRNA (t⁶A₃₇). YRDC-IN-1 selectively inhibits the translation of ANN codon-enriched FABP7, thereby reducing lipid droplet formation, increasing ROS, and reversing the acquired resistance of GBM to Temozolomide (TMZ) (HY-17364). YRDC-IN-1 can be used for the research of glioblastoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3120494-74-5
Formel: C₂₂H₂₀N₂O₃
Molecular Weight:360.41

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

YRDC-IN-1 Chemical Structure

CAS. Nr.: 3120494-74-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

In Vitro

YRDC-IN-1 (HY-Q66655) potently inhibits the proliferation of human glioma stem cells (MES28) after 48 h, with an IC₅₀ of 65.96 μM^[1].
YRDC-IN-1 (70 μM; 48 h) reduces the expression of FABP7 protein in TMZ-resistant glioblastoma cells LN18-R and glioblastoma stem cells MES28, but does not affect the level of YRDC^[1].
YRDC-IN-1 (70 μM; 48 h) preferentially inhibits the translation of ANN codon-enriched FABP7 in 293 T cells, and exerts a stronger inhibitory effect on the ANN-high-content FABP7 reporter gene compared with variants with low ANN content^[1].
YRDC-IN-1 (70 μM) sensitizes TMZ-resistant glioblastoma cells LN18-R and glioblastoma stem cells MES28 to TMZ, while overexpression of ANN-low FABP7 reverses this effect; in LN18-R cells, the IC₅₀ of TMZ decreases from 535.6 μM to 239.1 μM, and in MES28 cells, it decreases from 1066.0 μM to 467.8 μM^[1].
YRDC-IN-1 (70 μM; 48 h) reduces lipid droplet levels in TMZ-resistant LN18-R glioblastoma cells and MES28 glioblastoma stem cells, and overexpression of ANN-low FABP7 reverses this effect^[1].
YRDC-IN-1 (0-50 μM) acts synergistically with TMZ (0-600 μM) to inhibit the proliferation of TMZ-resistant LN18-R glioblastoma cells and MES28 glioblastoma stem cells, with their average ZIP synergy scores being 15.14 and 20.66, respectively^[1].
YRDC-IN-1 (70 μM; 4 days) potently inhibits the proliferation of human HuH-7 hepatocellular carcinoma cells, PANC-1 pancreatic cancer cells, HCT116 colorectal cancer cells, and SGC7901 gastric cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

human TMZ-resistant glioblastoma cells (LN18-R), glioblastoma stem cells (MES28)
Concentration:

70 μM
Incubation Time:

48 h
Result:

Did not alter YRDC protein levels.
Significantly reduced FABP7 protein levels in both LN18-R and MES28 cells.

Cell Proliferation Assay^[1]

Cell Line:

human hepatocellular carcinoma (HuH-7), pancreatic carcinoma (PANC-1), colorectal carcinoma (HCT116), gastric carcinoma (SGC7901) cells
Concentration:

70 μM
Incubation Time:

4 days
Result:

Significantly inhibited cell proliferation in all four cancer cell lines.
Reduced relative cell viability to ~2% in HuH-7 by day 4.
Reduced relative cell viability to ~3% in PANC-1 by day 4.
Reduced relative cell viability to ~3% in HCT116 by day 4.
Reduced relative cell viability to ~3% in SGC7901 by day 4.

In Vivo

YRDC-IN-1 (HY-Q66655) (10 mg/kg; i.p.; every 3-4 days; six administrations) significantly reduces GSC147-derived glioblastoma tumor volume and extends mouse survival^[1].
YRDC-IN-1 (10 mg/kg; i.p.; every 3-4 days; six administrations) significantly reduces MES28-derived glioblastoma tumor volume and extends mouse survival^[1].
YRDC-IN-1 (10 mg/kg; i.p.; twice weekly; three weeks) is well-tolerated in healthy BALB/c-nu mice with no significant toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c-nu (5-week-old female, intracranial injection of 5,000 patient-derived GSC147 cells)^[1]
Dosage:

10 mg/kg
Administration:

i.p.; every 3-4 days; six administrations
Result:

Reduced mean tumor volume to ~20 mm³ compared to vehicle control ~60 mm³.
Extended median survival time significantly.

Animal Model:

BALB/c-nu (5-week-old female, intracranial injection of 5,000 patient-derived MES28 cells)^[1]
Dosage:

10 mg/kg
Administration:

i.p.; every 3-4 days; six administrations
Result:

Reduced mean tumor volume to ~10 mm³ compared to vehicle control ~60 mm³.
Extended median survival time significantly.

Animal Model:

BALB/c-nu (5-week-old female, tumor-free)^[1]
Dosage:

10 mg/kg
Administration:

i.p.; twice weekly; three weeks
Result:

Did not induce significant body weight loss.
Caused no obvious pathological damage in major parenchymal organs.

Chemical Information

CAS. Nr. 3120494-74-5
Appearance Solid
Molecular Weight 360.41
Formel C₂₂H₂₀N₂O₃
SMILES

O=C(N1CCC2(CC1)OCC3=C2C=CC=C3)C4=CC=C(C5=CC=CN=C5)O4
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Oncogene

Targeting YRDC blocks codon-biased FABP7 translation and lipid droplet formation to overcome chemoresistance in glioblastoma. [Abstract]

2026 Jun;45(22):2155-2170. PMID: 42014887

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Zhang Y, et al. Targeting YRDC blocks codon-biased FABP7 translation and lipid droplet formation to overcome chemoresistance in glioblastoma. Oncogene. 2026;45(22):2155-2170. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

YRDC-IN-1

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

YRDC-IN-1

Publications Citing Use of MedChemExpress (MCE) YRDC-IN-1

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

YRDC-IN-1 Related Classifications

HY-Q66655 Related Classifications